热门资讯> 正文
礼来公司获得欧盟认可阿尔茨海默病药物
2025-07-25 21:01
- Despite a previous decision declining a potential marketing authorization application, Eli Lilly (NYSE:LLY) received backing from an expert panel of the EU drug regulator, the European Medicines Agency (EMA), for its Alzheimer’s treatment donanemab on Friday.
- The Indiana-based drugmaker said that the EMA’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on the anti-amyloid agent for a select group of adults with early symptomatic Alzheimer's disease.
- The CHMP opinion will next be reviewed by the European Commission, which is expected to make a final decision on the company’s MAA within the next several months, the company added.
- After CHMP issued a negative opinion on the drug marketed as Kisunla in March, denying a potential marketing authorization for the monthly infusion, Eli Lilly (NYSE:LLY) requested a reevaluation of the decision in the following month.
More on Eli Lilly
- Eli Lilly: Competition Melts Away
- Eli Lilly: Still Too Pricey To Buy
- Eli Lilly Comes Out As ADA Winner
- Former biotech exec George Tidmarsh to lead key FDA drug center
- Eli Lilly's Omvoh wins Health Canada approval for Crohn’s disease
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
